Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock

Edgewise Therapeutics' Chief Medical Officer, Joanne Donovan, has sold 9,441 shares of the company's stock in two transactions on August 12 and August 13, 2026. The sales totaled about $412,703, with prices per share ranging from $43.12 to $44.57. Currently, the stock is trading at $44.17, which is up 212% over the past year and 78% year-to-date.

Donovan's sales were primarily to meet tax obligations for the vesting of Restricted Stock Units, not discretionary. She also sold 2,919 shares on August 13 as part of a previously established trading plan. Prior to these sales, Donovan had acquired shares from the vesting of her RSUs and received new derivative securities, including RSUs and stock options.

After the reported transactions, Donovan now owns 8,625 shares and 32,500 unvested RSUs directly. Edgewise Therapeutics has recently sold its muscular dystrophy business to Servier for up to $2.65 billion, including an upfront payment and potential additional payments. Analysts have updated their assessments of EWTX, with Oppenheimer and Guggenheim raising their price targets to $51.

RBC Capital increased its target to $59, citing positive trial data for Edgewise's drug candidate '7500.